EverHint – SMA 20/50 Crossover – Top 3 Buy and Top 5 Sell Signals for Sep 11, 2026
Excerpt: 8 signals (from 17 total). Healthcare leads (7). price range $13-$534.
What This Signal Is
Detects fresh crossovers between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50). Uses two SMAs, making it more stable and less prone to false signals compared to EMA-based strategies. Well-suited for identifying medium-term trend changes with higher reliability.
Entry Criteria:
- Buy: SMA20 crosses above SMA50
- Sell: SMA20 crosses below SMA50
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 2-6 weeks | Risk level: Medium
Market Context
Broad market conditions on September 11, 2026 are decidedly constructive, with all three major indices posting gains approaching 1% and the S&P 500 clearing the 7,655 level. This synchronized advance across large-cap benchmarks signals broad-based risk appetite rather than narrow sector leadership, which tends to improve the reliability of trend-following strategies like the 20/50-day simple moving average crossover. When markets rise in unison, momentum signals are less likely to generate false positives caused by index-level divergence.
The VIX reading of 15.84, down sharply by over 11% on the day, is a particularly meaningful backdrop for SMA-based signals. Low and falling volatility compresses intraday price swings, which generally reduces whipsaw risk for crossover strategies that can otherwise be sensitive to short-term noise. With implied volatility retreating toward the lower end of a normal range, SMA crossovers are more likely to reflect genuine directional shifts rather than transient price spikes, improving signal quality across the 17 generated today.
Healthcare emerging as the top sector for today's signals aligns with a classic late-cycle or defensive rotation pattern, where investors maintain risk exposure but rotate toward more stable, earnings-resilient industries. In a low-volatility, broadly rising market environment, defensive sector leadership can indicate that institutional money is selectively positioning rather than aggressively chasing growth, suggesting a measured but sustained uptrend. This supports a favorable environment for holding SMA crossover positions with disciplined risk management, as trending conditions in defensive sectors tend to produce smoother, more tradeable price action.
🟢 Buy Signals (3 of 3 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | MCap |
|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | Healthcare | $263.51 | $16.4B |
| 2 | MDGL | Madrigal Pharmaceutica... | Healthcare | $534.49 | $12.3B |
| 3 | PGR | The Progressive Corpor... | Financial Services | $217.62 | $126.5B |
🔴 Sell Signals (5 of 14 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | MCap |
|---|---|---|---|---|---|
| 1 | AME | AMETEK, Inc. | Industrials | $241.85 | $55.4B |
| 2 | AMG | Affiliated Managers Gr... | Financial Services | $355.68 | $9.4B |
| 3 | BHVN | Biohaven Ltd. | Healthcare | $12.71 | $1.9B |
| 4 | CARG | CarGurus, Inc. | Consumer Cyclical | $34.42 | $3.3B |
| 5 | CHD | Church & Dwight Co., Inc. | Consumer Defensive | $94.15 | $22.3B |
Field Notes
Sector concentration: Healthcare (7), Industrials (3), Financial Services (3)
Data coverage: 0.0% insider (7d), 0.0% congressional (30d), 0.0% earnings, 23.5% news (7d)
Peer Analysis
BHVN (Biohaven Ltd.): Leads 5 peers: NTLA ($11.74), IMNM ($24.67), ABCL ($10.89), VERA ($35.05), ZBIO ($31.12)
ASND (Ascendis Pharma A/S): Leads 5 peers: IONS ($54.21), BBIO ($72.44), RVMD ($203.77), ROIV ($40.81), SMMT ($17.55)
PGR (The Progressive Corporation): Leads 5 peers: CB ($338.25), BBVA ($29.55), UBS ($54.58), TRV ($375.20), BAC ($62.69)
Recent Headlines
ASND (Ascendis Pharma A/S)
- Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX)
BHVN (Biohaven Ltd.)
- Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
- Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
- FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
- Baird reiterates Biohaven stock rating after regulatory update
- US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (7 signals) suggests sector-specific rotation.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Enjoying the updates? Liking, sharing, or subscribing helps bring this analysis to a wider audience.